Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Radford

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Journal of the National Cancer Institute|August 21, 2014
Risk of premature menopause after treatment for Hodgkin's lymphomaAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaRobert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
British Journal of Haematology|September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive settingToby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 29, 2014
An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicityLaura Cove-Smith, Neil Woodhouse, Adam Hargreaves, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Journal of the National Cancer Institute|August 21, 2014
Risk of premature menopause after treatment for Hodgkin's lymphomaAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Blood|August 15, 2019
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaRobert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
British Journal of Haematology|September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive settingToby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 29, 2014
An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicityLaura Cove-Smith, Neil Woodhouse, Adam Hargreaves, et al.
Pageof 11